LncRNA SNHG12 in extracellular vesicles derived from carcinoma-associated fibroblasts promotes cisplatin resistance in non-small cell lung cancer cells

Deli Tan, Gang Li, Peng Zhang, Chao Peng, and Bo He

Department of Thoracic Surgery, Chongqing Ninth People’s Hospital, Chongqing, China

ABSTRACT
Non-small-cell lung cancer (NSCLC) is defined as the most universally diagnosed class of lung cancer. Cisplatin (DDP) is an effective drug for NSCLC, but tumors are prone to drug resistance. The current study set out to evaluate the regulatory effect of long non-coding RNA (lncRNA) small nucleolar RNA host gene 12 (SNHG12) in extracellular vesicles (EVs) derived from carcinoma-associated fibroblasts (CAFs) on DDP resistance in NSCLC cells. Firstly, NSCLC cells were treated with EVs, followed by detection of cell activity, IC50 values, cell proliferation and apoptosis, and Cy3-SNHG12. We observed that CAFs-EVs promoted IC50 values and cell proliferation and inhibited apoptosis. In addition, we learned that lncRNA SNHG12 carried by CAFs-EVs into NSCLC facilitated DDP resistance of NSCLC cells. Furthermore, ELAV like RNA binding protein 1 (HuR/ELAVL1) binding to lncRNA SNHG12 and X-linked inhibitor of apoptosis (XIAP) was verified and RNA stability of XIAP was also verified CAFs-EVs promoted RNA stability and transcription of XIAP, while silencing HuR could partially-reverse this promoting effect. Further joint experimentation showed that silencing XIAP partially inhibited DDP resistance in NSCLC cells. Additionally, the tumor growth and the positive rate of Ki67 and HuR were detected, which showed that CAFs-oe-EVs promoted the tumor and the positive rate of Ki67, as well as the levels of lncRNA SNHG12, HuR, and XIAP in vivo. Collectively, our findings indicated that lncRNA SNHG12 carried by CAFs-EVs into NSCLC cells promoted RNA stability and XIAP transcription by binding to HuR, thus augmenting DDP resistance in NSCLC cells.

1. Introduction
Lung cancer, as the leading cause of cancer-related deaths, accounts for an extremely-high 1.6 million fatalities every year [1]. Non–small cell lung cancer (NSCLC), as the main subtype of lung cancer, makes up approximately 85% of lung cancer cases [2]. Meanwhile, cisplatin (DDP) is well-renowned for its anti-cancer effects and serves as the chemotherapeutic drug with the widest application and significant effect in a plethora of cancers, including gastric carcinoma, testicular carcinoma, and NSCLC [3–6]. However, DDP resistance, which can be innate or acquired, inevitably undermines the efficacy of DDP-based therapies, leading to ineffective clinical treatment [4,7,8]. Nonetheless, the hard-done work of our peers has shown that the development of DDP resistance is associated with the following molecular mechanisms: alterations in cellular accumulation, and an increase in DNA repair, as well as drug inactivation [9]. Hence, a further investigation of DDP resistance in NSCLC is urgent and needed.

Carcinoma-associated fibroblasts (CAFs) as activated fibroblasts at the tumor stroma are known to possess the ability to advance the progress of cancer through modifications to the primary tumor microenvironment (TME) [10]. Meanwhile, extracellular vesicles (EVs) are capable of altering the effects of recipient cells via transport of a variety of proteins, DNAs, and RNAs, and thus affect cellular processes [11]. It is also noteworthy that EVs exert crucial effects on the progression and metastatic evolution of primary tumors, owing to their role as the key medium of intercellular communication [12]. Moreover, CAFs also influence drug resistance in NSCLC by regulating TME, whereas EVs also exert the same effects on tumor occurrence and drug resistance in NSCLC by controlling signaling

CONTACT Bo He heb000628@163.com Department of Thoracic Surgery, Southwest Hospital, Army Medical University, Chongqing 400038, China

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
pathways [13,14]. Accordingly, CAFs-EVs were introduced as the prime focus of our study to explore the mechanism of DDP resistance in NSCLC cells.

Long non-coding RNAs (lncRNAs) are >200 nucleotides long, and function as a kind of RNA transcripts [15]. Meanwhile, EVs are also capable of carrying lncRNAs into NSCLC cells, such that lncRNAs can be adopted to regulate the drug resistance in NSCLC through platinum-based chemotherapy [16,17]. One such lncRNA, namely lncRNA small nucleolar RNA host gene 12 (SNHG12), is regarded as a kind of oncogene in various cancers, with lncRNA SNHG12 expressions also previously associated with drug resistance in NSCLC [18,19]. Herein, we speculated that lncRNA SNHG12 may be carried by CAFs-EVs into NSCLC cells, and further exerts an impact on DDP resistance in NSCLC cells.

Furthermore, RNA-binding proteins (RBPs) are heralded as important regulators of lncRNAs, such that lncRNAs serve a key regulatory role in the post-transcriptional regulation mediated by RBP [20]. Interestingly, certain proteins, acting as transcription repressors or activators, were previously indicated to promote tumor metastasis by regulating lncRNA SNHG12 [21]. Meanwhile, human antigen R (HuR/ELAVL1) is known as a member of the RBP family, while lncRNA SNHG12 is implicated in the growth of cancers via binding to HuR [22]. Meanwhile, the X-linked inhibitor of apoptosis protein (XIAP) is associated with cancer progression and cisplatin sensitivity [23,24], whereas XIAP was previously indicated to modulate chemoresistance in NSCLC [25]. In this study, we determined to investigate the role of CAFs-EVs in DDP resistance in NSCLC cells, and consequently, we raised a hypothesis that lncRNA SNHG12 may be carried by CAFs-EVs into NSCLC cells and then affect DDP resistance in NSCLC cells via the via HuR/XIAP axis. This study may provide a basic reference value and academic support for reducing DDP resistance in NSCLC cells in clinical treatment.

2. Materials and methods

2.1. Isolation and culture of primary fibroblasts

CAFs and normal fibroblasts (NFs) were obtained from human NSCLC tissues and adjacent non-cancerous tissues (at least 5 cm away from the tumor periphery of the same patient). All tissues were extracted at the Southwest Hospital, Army Medical University (Third Military Medical University) following the approval of the Ethical Committee of Southwest Hospital, Army Medical University (Third Military Medical University). Signed informed consents were obtained from all participants prior to specimen collection.

In accordance with a previously reported method [26], the primary fibroblasts were isolated and cultured. Briefly, phosphate-buffered saline (PBS; Gibco, Grand Island, NY, USA) was used to rinse the tissues for 60 min, then sliced into 1 × 1 mm pieces, and distributed in 6-well plates, and dried for 10–20 min. The dried tissue pieces were incubated in the Dulbecco’s modified Eagle’s medium/F12 (DMEM/F12), which comprised of 10% fetal bovine serum (FBS; Gibco), 100 U/mL penicillin, and 100 µg/mL streptomycin. The medium was cultured in a humidification incubator at 37°C with 5% CO2 in air. When the fibroblasts grew out of the tissue pieces, the cells were subjected to continual culture until the density reached 75%, followed by removal of the tissues. The medium was absorbed and then 2 mL of medium was added for the subsequent culture. Cell passage was performed when the cell density reached 80%.

2.2. Immunocytochemistry

Based on a previous study [27], the cleaned, acidified, and sterilized coverslips were placed into cell-culture dishes, and the cells were cultured on coverslips for 24–48 h. After the coverslips were covered with cells, the medium was removed. Following rinsing with PBS, the cells were fixed with 4% formaldehyde for 15 min, and then incubated in 0.3% Triton X-100 for 20 min. The cells were subsequently rinsed again with PBS, and cultured with 1% bovine serum albumin (BSA)
for 30 min, and then with primary antibody at 37°C for 1 h. Following another PBS rinse, the cells were cultured with the secondary antibody in a humidification incubator for 30 min. After another PBS rinse, the cells were stained with 2, 4-diaminobutyric acid, counterstained with hematoxylin, dehydrated, made transparent, and observed after sealing. The following antibodies were employed: rabbit monoclonal antibody alpha-smooth muscle actin (α-SMA; ab124964, dilution ratio of 1: 1000, Abcam, Cambridge, UK), rabbit monoclonal antibody vimentin (ab92547, dilution ratio of 1: 250, Abcam), and rabbit polyclonal antibody fibroblast activation protein (FAP; ab28244, dilution ratio of 1:1000, Abcam).

2.3. Isolation of EVs

Firstly, FBS without EVs was prepared. Subsequently, FBS was filtered through a 0.22 μm filter membrane, and the filtrate was placed in an ultra-high-speed centrifuge tube, then centrifuged at 120000 × g at 4°C for 90 min. The supernatant was gathered and collected. After rinsing with PBS, the cells were cultured in the complete medium of freshly prepared FBS without EVs [DMEM containing with 10% FBS (Gibco; 100 IU/mL penicillin, and 0.1 mg/mL streptomycin)] for 48 h. When the cells achieved 50% confluence, the medium was changed, and the cells were continually cultured for 48 h. Next, the medium was collected, centrifuged at 1000 × g for 10 min, and then filtered to obtain the conditioned medium. Subsequently, the EVs were separated from the conditioned medium by means of differential centrifugation. In other words, the conditioned medium was centrifuged at 300 × g for 10 min, and then centrifuged at 2000 × g for 20 min to remove cells. The cells were centrifuged at 100000 × g for 90 min to make the EVs into spheres. The precipitate was then resuspended in PBS and centrifuged at 100000 × g to collect the EVs again. Based on a previously reported method [28], the isolated EVs were quantified using a QuantumNANO nanoparticle detector (Izon Science, Christchurch, New Zealand) and scanning electron microscope (SEM), and its protein levels were detected using bicinchoninic acid (BCA) protein assay kits (Abcam). EVs with 100 μg/100 μL protein concentration were selected for subsequent experimentation. Cells were treated with 10 μM GW4869 for 48 h to block the release of EVs. The obtained conditional medium was used as a control.

2.4. Transmission electron microscopy (TEM)

The treated cells were rinsed with PBS and observed under a transmission electron microscope, in accordance with a previously published method [27]. Briefly, the cells were pretreated with 2.5% glutaraldehyde in PBS (pH 7.4) for 2 h, fixed in PBS with 1% osmium tetroxide for 2 h, cultured on luminescent copper mesh for 1 min, stained with 2% aqueous phosphotungstic acid, and then carefully filtered through filter papers to remove the excess buffer from the edge of the copper mesh. Subsequently, the cells were stained with 2% uranyl acetate (pH 7.0) for 40 s, and air-dried at room temperature for TEM at 80 keV.

2.5. Cell culture and treatment

NSCLC cell lines (A549 and HCC44) and human normal lung epithelial cell BEAS2B were procured from American Type Culture Collection (ATCC; Manassas, VA, USA). In accordance with a previous study [29], the obtained cells were cultured in Roswell Park Memorial Institute 1640 (RPMI-1640), comprising of 10% FBS (Gibco), 100 U/mL penicillin, and 100 U/mL streptomycin at 37°C with 5% CO2. The cells were treated with different concentrations of cisplatin (0, 1, 2, 4, 6, 8, and 10 μg/mL) for 48 h, followed by subsequent experimentation.

Sequences of oe-lncRNA SNHG12, si-HuR (si-HuR-1 and si-HuR-2), and si-XIAP (si-XIAP-1 and si-XIAP-2) and their corresponding negative controls were purchased from GenePharma (Shanghai, China). The cells were transfected according to the manufacturer instructions of Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), and retained in culture for 48 h for further analysis.
2.6. Cell counting kit-8 (CCK-8) assay

Based on a previously published method [30], Cell Counting Kit 8 (KeyGEN, Nanjing, China) was adopted to analyze the proliferation activity of cells. Briefly, the cells were seeded in 96-well plates at a density of $5 \times 10^3$/well. The cells adhered to the wall overnight, which were treated with different concentrations of cisplatin (0, 1, 2, 4, 6, 8, and 10 µg/mL) for 48 h in conformity with the manufacturer’s instructions. Subsequently, CCK-8 solution (10 µL/well) was added to the wells and the cells were cultured at 37°C for 2 h, and the absorbance was measured at 450 nm to quantify cell proliferation. The experiment was conducted 3 times independently, with at least 3 duplicate wells set for each group of cells in each experiment.

2.7. Colony formation assay

Based on a previous study [31], a colony formation assay was conducted to analyze the proliferation of NSCLC cells. Briefly, the cells were seeded in 6-well plates at a density of $1 \times 10^4$/well. After being cultured for 14 days, the cells were fixed with 4% paraformaldehyde for 30 min and dyed with 0.04% crystal violet (Beyotime, Shanghai, China) for 1 h. Subsequently, the formed colonies were photographed and counted under a microscope (Olympus, Tokyo, Japan). The experiment was repeated 3 times independently, with at least 3 duplicate wells set for each group of cells in each experiment.

2.8. Flow cytometry (FCM)

Based on a previously published method [32], flow cytometry was adopted to determine the apoptotic levels of NSCLC cells. In short, the transfected A549 and HCC44 cells were seeded in 24-well plates, respectively. After 48 h of the culture, the cells were extracted and subjected to apoptosis detection with Annexin V-FITC/PI double-staining kits (R&D SYSTEMS, Inc. MN, USA). The cells were stained with Annexin V-FITC and PI, and the apoptosis rate was detected by means of FCM (MoFloAstrios EQ). The detection wavelength of FITC was 530 nm and the detection wavelength of PI was 575 nm. The experiment was repeated 3 times independently, with at least 3 duplicate wells set for each group of cells in each experiment.

2.9. RNase-A and TritonX-100-treatment

Based on a previous study [33], CAFs-EVs were treated with 1 µg/mL RNase A (Invitrogen) or RNase A in combination with 0.1% Triton × 100 (Beyotime) at normal temperature. Subsequently, the expression patterns of IncRNA SNHG12 were detected by quantitative real-time polymerase chain reaction (qRT-PCR). The experiment was repeated 3 times independently, with at least 3 duplicate wells set for each group of cells in each experiment.

2.10. Fluorescent labeling and transfer of EVs

Based on a previous study [34], in order to identify the transfer of IncRNA SNHG12 in EVs, Cy3-labeled SNHG12 was transfected into CAFs. Subsequently, the CAFs expressing Cy3-SNHG12 were seeded into the upper chamber of Transwell 24-well plates, while NSCLC cells were seeded into the lower chamber of Transwell plates for coculture of 48 h. In addition, the NSCLC cytoskeletons were selectively stained with TRITC Phalloidin (YEASEN, Shanghai, China) or FITC Phalloidin (YEASEN, Shanghai, China). The results were observed with the help of a confocal microscope (Leica Microsystems, Mannheim, Germany).

2.11. qRT-PCR

The TRIzol reagent (Invitrogen) was adopted to extract the total RNA content from the different cells. In accordance with a previous study [35], the obtained RNA was reverse-transcribed into cDNA using reverse transcription kits (R&D SYSTEMS, Inc. MN, USA). For the measurement of cDNA, qRT-PCR was performed on a Bio-Rad Laboratories system (Berkeley, USA) in conformity with the instruction of the SYBR green kits (Thermo Fisher, Shanghai, China). The primers of PCR were shown in Table 1. The $2^{-\Delta\Delta Ct}$ method was adopted to calculate the relative
gene expression, with GAPDH as an internal reference. The experiment was repeated 3 times independently, with at least 3 duplicate wells set for each group of cells in each experiment.

2.12. Western blot assay

In accordance with a previous study [36], a Western blot assay was conducted to examine the protein levels. Total protein content of the cells was extracted using RIPA buffer (Sigma-Aldrich St. Louis, MO, USA), and protein detection kits were used to determine the protein concentration. Subsequently, the protein samples were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene fluoride (PVDF) membrane. After the PVDF membrane was sealed with 5% skim milk, the treated protein samples were cultured overnight with the primary antibodies rabbit monoclonal antibody HuR (ab200342, dilution ratio of 1: 1000, Abcam) and the rabbit polyclonal antibody β-actin (ab8227, dilution ratio of 1: 1000, Abcam). The following day, the proteins were cultured with the secondary antibody goat anti-rabbit IgG (ab6721, dilution ratio of 1: 2000, Abcam) at normal temperature for 2 h. The protein bands were observed with the help of enhanced chemiluminescent substrate kits (Millipore, Billerica, MA, USA). Subsequently, the proteins were quantified using the Quantity One software (Bio-Rad Laboratories, USA). β-actin was employed as the internal reference, and the experiment was repeated independently 3 times, with at least 3 duplicate wells set for each group of cells in each experiment.

2.13. Bioinformatics

The binding of IncRNA SNHG12 to HuR and binding of HuR to XIAP were predicted with the help of an online database [http://www.rna-society.org/rnainter/] [37].

2.14. RNA pull-down

Based on a previously published method [38], the bindings of RNA-binding protein HuR to IncRNA SNHG12 and XIAP were respectively detected using an RNA pull-down assay. Firstly, A549 or HCC44 cells were lysed with a protein lysis buffer (Thermo Fisher), and biotin was used to label IncRNA SNHG12 (Bio-SNHG12) or XIAP (Bio-XIAP), with biotinylated probes serving as the negative control. Subsequently, the probes conjugated with biotin were incubated with magnetic beads for 2 h. Next, the cell lysis buffer was cultured overnight at 4°C with the probes. After the culture, the bond RNA was rinsed with washing buffer and analyzed using qRT-PCR. The experiment was repeated 3 times independently, with at least 3 duplicate wells set for each group of cells in each experiment.

2.15. RNA immunoprecipitation (RIP)

Based on a previous study [39], the bindings of HuR to IncRNA SNHG12, and XIAP were respectively verified using a RIP assay. Briefly, RIP was conducted using a Magna RIP RNA-Binding Proteins immunoprecipitation kit (R&D SYSTEMS, Inc.MN, USA) in accordance with the manufacturer’s instructions. Total RNA content (input control) of each antibody and the isotype control precipitate (IgG) were simultaneously detected. The co-precipitated RNA was pulled-down with protein G beads and detected by means of qRT-PCR. The experiment was repeated 3 times independently, with at least 3 duplicate wells set for each group of cells in each experiment.
2.16. RNA stability

To investigate the mRNA decay rate of XIAP mRNA, each group of cells was treated with 5 μg/mL of actinomycin D to inhibit or promote the RNA transcription, based on a previously published method [40]. Total RNA content was extracted from the cells at different time points, and the expression patterns of XIAP mRNA were analyzed by qRT-PCR, with GAPDH serving as the internal reference. In addition, the levels of XIAP mRNA were detected after the addition of actinomycin D. The experiment was repeated 3 times independently, with at least 3 duplicate wells set for each group of cells in each experiment.

2.17. Animal study

A total of 36 BALB/c nude mice (aged 4–5 weeks, weighing 15–18 g) were procured from Animal Experimental Center of Huazhong University of Science and Technology [License No.: SCXK (Hubei) 2021–0009, Wuhan, Hubei, China]. In accordance with a previous study [34], A549 cell suspension was subcutaneously injected into the back of all nude mice (5 × 10⁶ cells/mL/mouse). When the tumor volume reached 50–100 mm³, the mice were randomly classified into three groups, 12 for each group. Cisplatin (6 μg/mL, 4 mg/kg), CAFs-EVs (CAFs-NC-EVs, 100 μg/100 μL/mouse) or CAFs-EVs (CAFs-oe-EVs, 100 μg/100 μL/mouse) with over-expression of lncRNA SNHG12 were intraperitoneally injected into mice. Simultaneously, the control mice were injected with cisplatin and PBS buffer instead of the EVs. The tumor growth of nude mice was measured using vernier calipers every 7 d for consecutive 28 d, and the tumor volume (mm³) = (length × width ²)/2 was calculated. The nude mice were injected with 200 mg/kg of pentobarbital sodium for euthanasia on the 28th d. After death, mice tumors were removed. Six tumors randomly selected from each group were fixed with 10% paraformaldehyde solution for 24 h, dehydrated with gradient ethanol, embedded with paraffin, and then made into 4 μm tissue sections. Subsequently, the tumors of the remaining mice were subjected to tissue homogenization to measure the levels of lncRNA SNHG12, HuR, and XIAP in tumors. All animal experimentation protocols were approved by Animal Ethics Society of Southwest Hospital, Army Medical University (Third Military Medical University) and in conformity with the Guidelines for the Care and Use of Laboratory Animals [41]. Extensive efforts were made to minimize the number and suffering of the experimental animals.

2.18. Immunohistochemistry (IHC)

Based on a previous study [42], IHC was conducted to examine the expressions of Ki67 and HuR. In brief, the sections were dewaxed with xylene and hydrated with gradient ethanol, added with 0.01 M citric acid buffer for antigens retrieval, cultured with 3% H₂O₂ for 15 min, and then cultured with goat serum for 30 min at normal temperature. Subsequently, the sections were cultured overnight at 4°C with the rabbit polyclonal antibody Ki67 (ab15580, dilution ratio of 1:1000, Abcam) or rabbit monoclonal antibody HuR (ab200342, dilution ratio of 1: 500, Abcam), and then cultured with the secondary anti-goat anti-rabbit IgG H&L (ab6721, dilution ratio of 1:1000, Abcam) for 1 h at normal temperature. After PBS rinsing, the sections were sequentially stained with diaminobenzidine and hematoxylin, and sealed with a neutral resin. The images were obtained using a fluorescence microscope (Leica Microsystems Inc., Buffalo Grove, IL, USA). The expression levels of Ki67 and HuR were analyzed using the ImageJ software.

2.19. Statistical analysis

SPSS21.0 statistical software (IBM SPSS Statistics, Chicago, IL, USA) and GraphPad Prism 8.0 software (GraphPad Software Inc., San Diego, CA, USA) were adopted for statistical analyses and mapping of data. Measurement data were presented as mean ± standard deviation. First, normality and homogeneity of variance were tested to verify that the data conformed to the normal distribution and the homogeneity of variance. The t-test was adopted for analyses between two groups. One-way ANOVA or two-way ANOVA was performed for comparisons among multiple
groups, and Tukey’s multiple comparisons test was conducted for post-hoc test. The p value was obtained from the two-sided test, and a value of $p < 0.05$ was regarded statistically significant.

3. Results

In an effort to explore the effects of CAFs-EVs on DDP resistance in NSCLC cells, we speculated that CAFs-EVs may carry lncRNA SNHG12 into NSCLC cells and regulate DDP resistance in the cells. The final experimental results demonstrated that lncRNA SNHG12 carried by CAFs-EVs promoted the RNA stability of XIAP mRNA and the transcription of XIAP via binding to RNA-binding protein HuR, thus augmenting DDP resistance in NSCLC cells.

3.1. Identification of CAFs and CAFs-EVs

The TME plays a crucial role in protecting tumor cells from chemotherapeutic drugs that may lead to drug resistance. Meanwhile, CAFs as an important contributor of TME, have been previously demonstrated to be implicated in the drug resistance of NSCLC cells [13]. In addition, CAFs-EVs are closely-related to drug resistance in NSCLC cells [14]. Therefore, we isolated CAFs from the NSCLC tissues, and NFs from paracancerous tissues. Microscopic observation revealed that the cells were spindle-shaped, with the oval nucleus at the center and cytoplasmic processes, which are typical features of fibroblasts (Figure 1a). In addition, we found that the expression levels of the three fibroblast markers α-SMA, vimentin, and FAP, were higher in CAFs compared to those in NFs (Figure 1b). Subsequently, we extracted and observed the NF-EVS and CAFs-EVs using an electron microscope, which illustrated that NF-

![Figure 1. Identification of CAFs and CAFs-EVs. CAFs and EVs were extracted from NSCLC tissue. A: Microscope was used to observe the morphology of CAFs; B: Immunocytochemistry was adopted to detect the expressions of α-SMA (smooth muscle alpha-actin), vimentin and FAP (fibroblast activation protein) in CAFs; C: Electron microscope was used to observe the morphology of CAFs-EVs; D: Nanoparticle tracking analysis (NTA) was performed to analyze the size and concentration of EVs; E: Western blot was used to test the levels of EVs-specific markers CD63, CD81, and Calnexin. The cell experiment in panels C-D was repeated 3 times independently.]
EVS and CAFs-EVs were round particles with the size of about 50–150 nm, and both presented with bilayer membranes (Figure 1c). The average particle sizes of NF-EVS and CAFs-EVs were calculated to be 107.8 ± 5.6 nm and 123.6 ± 6.4 nm, respectively, while the concentrations were approximately 45,000/mL and 46,000/mL, respectively (Figure 1d). Then, we treated the CAFs or NFs with the EVs inhibitor GW4869 and detected the expression patterns of EVs-specific positive markers CD63 and CD81, as well as the negative marker Calnexin. It was found that CD63 and CD81 expressions were detected in NFs-EVS and CAFs-EVs, but the expression of Calnexin didn’t show. Meanwhile, in NFs and CAFs with the addition of GW4869, neither Calnexin, CD63, nor CD81 were detected (Figure 1e). Altogether, these findings indicated that CAFs and CAFs-EVs were successfully extracted.

### 3.2. CAFs-EVs promoted DDP resistance in NSCLC cells

To explore the regulatory effect of CAFs-EVs on DDP resistance in NSCLC cells, we first adopted CAFs-EVs or NFs-EVs to co-culture with NSCLC cells, and the treated NSCLC cells (A549 and HCC44) were subjected to treatment with different doses of DDP. By detecting the half inhibitory concentration (IC₅₀ values) of DDP, we observed that the IC₅₀ values after treatment of CAFs-EVs were markedly higher than those in NFs-EVS (p < 0.05, Figure 2a). Based on the results of IC₅₀ values, we selected 6 μg/mL dosage of DDP to treat A549 cells, and 5 μg/mL dosage of DDP to treat HCC44 cells in subsequent experiments. Following treatment with CAFs-EVs, the proliferation of NSCLC cells was found to be increased (p < 0.05, Figure 2b), while there was a reduction in apoptosis levels (p < 0.05, Figure 2c). To verify our hypothesis that CAFs-EVs may promote DDP resistance in NSCLC cells, we treated CAFs or NFs with the EVs inhibitor GW4869, and then extracted the EVs. Subsequently, the extracted CAFs-EVs or NFs-EVs were co-cultured with NSCLC cells, and then subjected to treatment with different doses of DDP to detect cell resistance. It was found that compared with CAFs-EVs treatment, the IC₅₀ values of DDP were reduced in NSCLC cells treated with GW4869 (p < 0.05, Figure 2a), the proliferation capacity of NSCLC cells was reduced ((p < 0.05, Figure 2b), in addition to increased apoptosis levels (p < 0.05, Figure 2c). In summary, these findings suggested that CAFs-EVs promoted DDP resistance in NSCLC cells.

### 3.3. LncRNA SNHG12 was carried by CAFs-EVs into NSCLC cells

A large number of factors can be carried by EVs into NSCLC cells which play a role in NSCLC, including lncRNAs [16,43,44]. Following literature review and selection of related genes, we speculated that EVs may carry the following factors to exert an impact in NSCLC: lncRNA-LINC00662, lncRNA-TBILA, lncRNA-SNHG12, miR-744, and miR-378 [19,43,45–47]. Subsequently, we detected the expression patterns of the above factors in NSCLC cells, which revealed that lncRNA SNHG12 exhibited the highest expression in NSCLC cells (p < 0.05, Figure 3a), which is in accordance with trends uncovered in previous studies [18,19,48,49]. In addition, the detection results illustrated that the expression levels of lncRNA SNHG12 in CAFs-EVs were significantly higher than those in NFs-EVS (p < 0.05, Figure 3b), whereas CAFs-EVs treatment brought about up-regulated the expression of lncRNA SNHG12 in NSCLC cells (p < 0.05, Figure 3c). Next, we treated CAFs-EVs with Rnase A or Rnase A in combination with Triton X-100, and found that individual treatment with Rnase A in combination with Triton X-100 reduced the expression of lncRNA SNHG12 (p < 0.05, Figure 3d), indicating that lncRNA SNHG12 was encapsulated in CAFs-EVs. In addition, following co-culture of Cy3-SNHG12-labeled CAFs with NSCLC cells for 48 h, fluorescence-labeled SNHG12 was observed in NSCLC cells under a confocal microscope (Figure 3e), which suggested that lncRNA SNHG12 was transferred from CAFs to NSCLC cells via EVs.

### 3.4. LncRNA SNHG12 carried by CAFs-EVs into NSCLC cells and promoted DDP resistance in NSCLC cells

LncRNA expressions are associated with DDP resistance and promotion of DDP resistance through repairing DNA damage [18]. In
addition, previous studies have shown that lncRNA SNHG12 promotes resistance to certain tumor drugs [19,50–52]. Accordingly, we hypothesized that lncRNA SNHG12 was carried by CAFs-EVs into NSCLC cells and then played a role in DDP resistance. To verify the said hypothesis, oe-SNHG12 was transfected into CAFs (p < 0.05, Figure 4a) and the expression of lncRNA SNHG12 in CAFs was successfully up-regulated. Subsequently, CAFs-EVs were isolated, and the expression of lncRNA SNHG12 in CAFs-EVs was also found to be up-regulated (Figure 2).
regulated \( p < 0.05 \), Figure 4b). Next, we cultured NSCLC cells with CAFs-EVs (CAFs-oe-EVs) over-expressing lncRNA SNHG12 and then found that the expression of lncRNA SNHG12 in NSCLC cells was also up-regulated \( p < 0.05 \), Figure 4c). Moreover, we observed that expression levels of lncRNA SNHG12 in NSCLC cells were increased, while the IC\(_{50}\) values of NSCLC cells were increased \( p < 0.05 \), Figure 4d), the proliferation capacity was increased \( p < 0.05 \), Figure 4e), and apoptosis levels were reduced \( p < 0.05 \), figure 4f). Altogether, these findings illustrated that lncRNA SNHG12 was carried by CAFs-EVs into NSCLC cells and promoted DDP resistance in NSCLC.

3.5. LncRNA SNHG12 promoted RNA stability and XIAP transcription by binding to HuR

LncRNAs have been previously shown to bind to RBPs to regulate cancers [53]. One such lncRNA, namely lncRNA SNHG12, is also known to bind to HuR, and thus confer regulatory effects on cancers [21,22,54]. This is particularly noteworthy as HuR is up-expressed in NSCLC [55]. Accordingly, we predicted the binding of lncRNA SNHG12 to HuR using an online database (http://www.rna-society.org/rnainter/) (Figure 5a), and further verified the binding of lncRNA SNHG12 to HuR by means of RNA pull-down and RIP assay \( p < 0.05 \), Figure 5b-c). Previous studies have suggested that XIAP promotes DDP resistance by inhibiting the apoptosis of NSCLC cells [25]. Thereafter, we...
predicted the binding of HuR to XIAP using the same online database (http://www.rna-society.org/rnainter/) (Figure 5a), and validated the binding of HuR to XIAP through RNA pull-down and RIP assay ($p < 0.05$, Figure 5d-e). HuR is further known as the most common RBP that stabilizes mRNA, whereas mRNA stability plays an important role in tumorigenesis [56]. Subsequently, we explored the effects of lncRNA SNHG12 and HuR on RNA stability and transcription of XIAP and ...
found that CAFs-EVs promoted the RNA stability and up-regulated XIAP mRNA levels in NSCLC cells \((p < 0.05, \text{Figure 5g-h})\). In addition, we transfected si-HuR into NSCLC cells to down-regulate the expression of HuR \((p < 0.05, \text{figure 5f})\), and si-HuR-1 was chosen due to its better silencing efficiency to conduct a joint experiment with CAFs-EVs. It was found that the silencing HuR partially reversed the promotion of CAFs-EVs on RNA stability and mRNA levels of XIAP \((p < 0.05, \text{figure 5i})\).
Figure 5g-h). Together, these findings illustrated that lncRNA SNHG12 promoted RNA stability and transcription of XIAP by binding to HuR.

3.6. Silencing XIAP partially-reversed the promotion of lncRNA SNHG12 on DDP resistance in NSCLC cells

Our previous findings highlighted that lncRNA SNHG12 could promote RNA stability, as well as transcription of XIAP by binding to HuR. To further explore whether this mechanism could exert a regulatory function on DDP resistance in NSCLC cells, we firstly transfected si-XIAP into NSCLC cells to down-regulate the mRNA levels of XIAP ($p < 0.05$, Figure 6a), with si-XIAP-1 exhibiting better silencing efficiency was selected for a combined experiment with CAFs-oe-EVs. The results illustrated that, following DDP treatment, silencing XIAP reversed the improvement in IC$_{50}$ values of NSCLC cells by CAFs-oe-EVs ($p < 0.05$, Figure 6b), in addition to countering the effects of CAFs-oe-EVs on the promotion of proliferation ability and inhibition of apoptosis of NSCLC cells ($p < 0.05$, Figure 6c-d). Overall, these findings indicated that silencing XIAP partially reverses the promotion of lncRNA SNHG12 on DDP resistance in NSCLC cells.

3.7. LncRNA SNHG12 carried by CAFs-EVs promoted the growth of NSCLC and DDP resistance in vivo

To further validate that lncRNA SNHG12 carried by CAFs-EVs into NSCLC cells promoted DDP resistance in NSCLC cells, we performed a subcutaneous tumorigenesis experiment in nude mice, and DDP and CAFs-EVs over-expressing lncRNA SNHG12 were injected into the mice. Analyses of tumor size and weight revealed that CAFs-oe-EVs promoted tumor growth ($p < 0.05$, Figure 7a-b). The positive rate of Ki67 in tumors was also detected using IHC, which illustrated that the positive rate of Ki67 in tumors was increased following CAFs-oe-EVs treatment ($p < 0.05$, Figure 7c). The expression patterns of lncRNA SNHG12, the levels of XIAP mRNA and the protein expression of HuR in tumors were also detected, which revealed that all the aforementioned levels were up-regulated in tumors after CAFs-oe-EVs treatment ($p < 0.05$, Figure 7d-f). In conclusion, the aforementioned findings indicated that lncRNA SNHG12 carried by CAFs-EVs promoted the growth of NSCLC tumors and DDP resistance in vivo.

4. Discussion

Non-small cell lung cancer (NSCLC) is the leading subtype of lung cancer, accounting for over 85% of diagnosed cases across the world, while only 15% of patients survive for 5 years after diagnosis [57]. The advent of Cisplatin (DDP) has greatly improved the outcomes of NSCLC, however DDP resistance during the malignancy is known to impede the clinical effects of NSCLC treatment [58]. In the current study, we sought to investigate the role of CAFs-EVs in DDP resistance in NSCLC cells, and uncovered that lncRNA SNHG12 carried by CAFs-EVs could stabilize RNA stability and transcription of XIAP by binding to HuR, and further augment the proliferation and limit the apoptosis of NSCLC cells, and finally promote DDP resistance in NSCLC cells.

DDP resistance serves as an unavoidable clinical obstacle in the course of treatment of various cancers, including ovarian cancer and NSCLC [59,60]. Meanwhile, carcinoma-associated fibroblasts (CAFs) are known to provide the essential TME for the invasion and metastasis of tumors, due to their ability to interact with cancer cells and other types of stromal cells and promote the drug resistance of cancers, such as breast cancer and oral squamous carcinoma [61–64]. Interestingly, recent studies have reported that PKM2, an important regulator of the Warburg effect, could be carried by EVs that were from hypoxic DDP-resistant cells to CAFs, and play a role in the promotion of chemotherapy resistance of sensitive cells [65]. Similarly, there is much evidence to suggest that CFA and CAF-derived EVs (CFAs-EVs) are implicated in the underlying mechanism of drug resistance in NSCLC [13,14,18]. To elaborate the said mechanism of CAFs-EVs in DDP resistance in NSCLC, firstly, we cultured CAFs-EVs or NFs-EVs with NSCLC cells, and the NSCLC cells (A549 and HCC44) were subjected to treatment with different doses of DDP.
Figure 6. Silencing XIAP partially reversed the promotion of lncRNA SNHG12 on DDP resistance in NSCLC cells. NSCLC cells were transfected with si-XIAP (si-XIAP-1, si-XIAP-2) to down-regulate the expression of XIAP, and si-NC was used as negative control. A: qRT-PCR was used to verify the transfection efficiency of XIAP; si-XIAP was in combination with CAFs-oe-EVs (CAFs-EVs of overexpression SNHG12) for a joint experiment; B: CCK-8 assay was conducted to examine the cell activity of NSCLC and the half inhibitory concentration (IC_{50}) of DDP; C: Colony formation assay was performed to detect the proliferation capacity of NSCLC cells; D: Flow cytometry was used to test the apoptotic level of NSCLC cells. The cell experiment was repeated 3 times independently, and data were expressed as mean ± standard deviation. Data in panel A was analyzed using one-way ANOVA and data in panels B-D were analyzed using one-way ANOVA, followed by Tukey's post-hoc test, *p < 0.05.
Subsequent findings illustrated that IC$_{50}$ values were markedly higher in cells after treatment of CAFs-EVs compared to those treated with NFs-EVs. The NSCLC cells (A549 cells and HCC44 cells) were treated with DDP, and it was found that the proliferation of NSCLC cells was increased, while the apoptosis was decreased following treatment with CAFs-EVs. To validate our hypothesis that CAFs-EVs promoted DDP resistance in NSCLC, we subjected the CAFs or NFs to treatment with an EVs inhibitor, GW4869, and then the CAFs-EVs and NFs-EVs were extracted and cultured with NSCLC. Different doses of DDP were chosen to treat the NSCLC cells. We observed that treatment with GW4869 brought about decreased IC$_{50}$ values of cells, diminished cell proliferation of NSCLC, in addition to increased cell apoptosis. In accordance with our findings, prior studies have documented that EVs are capable of mediating DDP resistance, and

Figure 7. LncRNA SNHG12 carried by CAFs-EVs promoted the growth of NSCLC and DDP resistance in vivo. The nude mice were injected with A549 cell suspension to conduct a subcutaneous tumorigenesis experiment, then DDP (6 μg/mL, 4 mg/kg) and CAFs-NC-EVs or CAFs-oe-EVs overexpressing SNHG12 were intraperitoneally injected into nude mice. A: the volume of the tumor body within 15 d was measured; B: the weight of the tumor body on the 15th d was measured; C: IHC was performed to detect the positive rate of Ki67 in tumors; D: IHC was conducted to detect the positive rate of HuR in tumors; E-F: qRT-PCR was used to detect the levels of SNHG12 and XIAP in vivo. N = 6; the cell experiment was repeated 3 times independently, and data were expressed as mean ± standard deviation. Data in panel A was analyzed using two-way ANOVA and data in panels B-F were analyzed using one-way ANOVA, followed by Tukey’s post-hoc test, * p < 0.05.
lncRNA POU3F3 carried by EVs regulates the differentiation and activation of NFs to CAFs, and thus augments DDP resistance in tumor cells [66,67]. Altogether, the aforementioned findings and shreds of evidence indicate that CAFs-EVs enhanced DDP resistance in NSCLC cells.

Additionally, EVs are known to possess the ability to carry lncRNAs into NSCLCs to modulate the progression of numerous malignancies [43,44]. One such lncRNA, namely lncRNA SNHG12, was previously found to be up-regulated in human osteosarcoma cells and NSCLC cells, along with the promotion of cell growth and proliferation [18,49]. Subsequent experimentation in our study that among the various factors that may be carried by EVs to influence NSCLC, lncRNA SNHG12 exhibited the highest expression in NSCLC cells. Hence, we speculated that CAFs-EVs may carry lncRNA SNHG12 into NSCLC cells. We observed that the expression levels of lncRNA SNHG12 in CAFs-EVs were higher than those in NFs-EVs, while further promoted following treatment with CAFs-EVs. In addition, lncRNA SNHG12 expression levels were decreased only after treatment with RNase A in combination with Triton X-100, which suggested that lncRNA SNHG12 was encapsulated in CAFs-EVs. Additionally, we came across fluorescence-labeled SNHG12 in NSCLC cells cultured with Cy3-SNHG12-labeled CAFs. To our knowledge, our study is the first-of-its-kind to prove that EVs transferred lncRNA SNHG12 from CAFs to NSCLC cells.

Furthermore, lncRNAs are well-established to be associated with chemoresistance in a plethora of cancers, such as DDP resistance, trastuzumab resistance, and gefitinib resistance [68–71]. Similarly, various studies have indicated that lncRNA SNHG12 may influence the development of tumors by virtue of promoting drug resistance [50,51]. Herein, we speculated that lncRNA SNHG12 carried by CAFs-EVs may also play a role in DDP resistance in NSCLC cells. Thereafter, oe-SNHG12 was transfected into the CAFs to increase the expression of lncRNA SNHG12 in CAFs. Isolation of CAFs-EVs demonstrated that lncRNA SNHG12 was notably highly-expressed in CAFs-EVs. Subsequently, CAFs-EVs over-expressing lncRNA SNHG12 (CAFs-oe-EVs) were cultured with the NSCLC cells, and further detection illustrated that lncRNA SNHG12 expression levels were increased in NSCLC cells, the IC_{50} values of NSCLC cells were increased, while cell proliferation was increased and apoptosis was reduced. Meanwhile, a prior study also documented up-regulation of lncRNA SNHG12 in NSCLC cells, such that knockdown of lncRNA SNHG12 exerted a diminishing effect on cellular proliferation of NSCLC cells, and thus enhanced DDP sensitivity in NSCLC cells [48]. Collectively, these findings make it plausible to suggest that lncRNA SNHG12 was carried by CAFs-EVs into NSCLC cells and promoted DDP resistance in NSCLC cells.

On a separate note, there is much evidence to highlight that the RNA-binding protein HuR, exerts regulatory functions on the growth of cells and the pathogenesis of cancers, while also being highly-expressed during the course of NSCLC [55,72]. It is noteworthy that lncRNAs are capable of modulating various cancers via binding to RBP, and we accordingly speculated whether the binding of lncRNA SNHG12 and HuR could have an impact on cancers [54,73,74]. In addition, a previous study indicated that X-linked inhibitor of apoptosis protein (XIAP) could play a role in the modulation of DDP resistance in NSCLC cells [25]. Thereafter, we sought to explore the potential interaction between these factors and raised a speculation that the lncRNA SNHG12/HuR/XIAP pathway may play a role in DDP resistance in NSCLC cells. Subsequently, we validated the presence of the binding relationship between HuR and lncRNA SNHG12 and XIAP with the help of RNA pull-down and RIP assays. Meanwhile, RBPs are known to regulate various aspects of cancers and play a unique role in stabilizing mRNA, which could affect the progression of tumors [75,76]. Accordingly, we explored the functions of lncRNA SNHG12 and HuR on RNA stability and transcription of XIAP. We learned that CAFs-EVs promoted RNA stability and up-regulated XIAP mRNA levels in NSCLC cells. Consequently, we transfected si-HuR into the NSCLC cells to down-regulate the expression of HuR, which were then subjected to a joint experiment with CAFs-EVs. The obtained findings illustrated that silencing HuR could partially restore the promotion of CAFs-EVs on RNA stability and mRNA levels of XIAP. Much in
accordance with our discoveries, prior studies have shown that XIAP serves as a regulatory target of HuR, and the expression and mRNA stability of XIAP were closely regulated by HuR, such that silencing HuR exerted a diminishing effect on the protein and mRNA levels of XIAP [77,78]. Overall, the aforementioned findings suggested that lncRNA SNHG12 improved RNA stability and up-regulated the transcription of XIAP by binding to RBP HuR.

To further elaborate the function of XIAP on DDP resistance in NSCLC cells, we selected si-XIAP-1 that exhibited the most profound silencing effect for combined experimentation with CAFs-oe-EVs. We found that, following DDP treatment, silencing of XIAP reversed the improvement of CAFs-oe-EVs on IC50 values in NSCLC cells, the promotive effect of CAFs-oe-EVs on cell proliferation, and the inhibitory effect of CAFs-oe-EVs on cell apoptosis. Through much-valuable literature review, we learned that DDP induces cancer cell apoptosis by down-regulating XIAP, whereas silencing XIAP could decrease DDP resistance in NSCLC cells [25,79], which is in accordance with our findings. Together, these findings indicated that silencing XIAP partially reversed the promotion of lncRNA SNHG12 on DDP resistance in NSCLC cells.

Interestingly, the expression of lncRNA SNHG12 was also previously associated with the progression of tumors [50,80]. To further explore the mechanism of lncRNA SNHG12 carried by CAFs-EVs in DDP resistance in NSCLC, an animal experiment was conducted. We found that CAFs oe-EVs promoted the growth of NSCLC, Ki67 positive rate, in addition to up-regulating the expressions of lncRNA SNHG12, XIAP mRNA levels, and HuR protein. Moreover, lncRNA SNHG12 was previously found to be highly-expressed in other human tumors, wherein over-expression of lncRNA SNHG12 facilitated the growth of tumors and inhibited drug sensitivity [52,81,82]. Altogether, the abovementioned findings suggested that lncRNA SNHG12 carried by CAFs-EVs promoted the growth of NSCLC and DDP resistance in vivo.

5. Conclusion

In summary, our findings revealed that lncRNA SNHG12 carried by CAFs-EVs promoted the RNA stability of XIAP mRNA and XIAP transcription via binding to HuR, and thus facilitating DDP resistance in NSCLC cells. Our study explored that lncRNA SNHG12 carried by CAFs-EVs played a role in DDP resistance in NSCLC cells, for the first time, which may provide a promising direction for NSCLC in clinical treatment. However, we only investigated the mechanism of lncRNA SNHG12 carried by CAFs-EVs in DDP resistance in NSCLC cells, and failed to explore the involvement of other factors carried by CAFs-EVs in the DDP resistance NSCLCs. In addition, our study only detected the RNA stability and transcription of XIAP but failed to investigate the protein level of XIAP. Lastly, we didn’t detect the differential gene and lncRNA expression profiles in the experiments by microarrays. We shall continue to investigate the mechanism of other factors carried by CAFs-EVs in DDP resistance in NSCLC cells in our future endeavors and verify the mechanism of lncRNA SNHG12 carried by CAFs-EVs in DDP resistance in NSCLC cells through animal experimentation.

Highlights

- CAFs-EVs promote DDP resistance in NSCLC cells.
- CAFs-EVs carry lncRNA SNHG12 into NSCLC cells.
- LncRNA SNHG12 binds to HuR to promote RNA stability and transcription of XIAP.
- Silencing XIAP averts the promotion of lncRNA SNHG12 on DDP resistance in NSCLCs.
- LncRNA SNHG12 carried by CAFs-EVs promotes the growth of NSCLC and DDP resistance.

Acknowledgements

Not applicable.

Data availability

The data that support this study are available from the corresponding author upon reasonable request.
Disclosure statement
No potential conflict of interest was reported by the author(s).

Funding
The author(s) reported there is no funding associated with the work featured in this article.

ORCID
Bo He http://orcid.org/0000-0003-3773-6516

References
[1] Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454.
[2] Broderick SR. Adjuvant and neoadjuvant immunotherapy in non-small cell lung cancer. Thorac Surg Clin. 2020;30(2):215–220.
[3] Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378.
[4] Ghosh S. Cisplatin: the first metal based anticancer drug. Bioorg Chem. 2019;88:102925.
[5] Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol. 2015;26(1):141–148.
[6] de Vries G, Rosas-Plaza X, van Vugt M, et al. Testicular cancer: determinants of cisplatin sensitivity and novel therapeutic opportunities. Cancer Treat Rev. 2020;88:102054.
[7] Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–1883.
[8] Wang R, Chen C, Kang W, et al. SNHG9 was upregulated in NSCLC and associated with DDR-resistance and poor prognosis of NSCLC patients. Am J Transl Res. 2020;12(8):4566–4646.
[9] Amable L. Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 2016;106:27–36.
[10] Kong J, Tian H, Zhang F, et al. Extracellular vesicles of carcinoma-associated fibroblasts creates a pre-metastatic niche in the lung through activating fibroblasts. Mol Cancer. 2019;18(1):175.
[11] Hua Q, Xu W, Shen X, et al. Dynamic changes of plasma extracellular vesicle long RNAs during peripерative period of colorectal cancer. Bioengineering. 2021;12(1):3699–3710.
[12] Becker A, Thakur BK, Weiss JM, et al. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell. 2016;30(6):836–848.
[13] Chen C, Hou J, Yu S, et al. Role of cancer-associated fibroblasts in the resistance to antitumor therapy, and their potential therapeutic mechanisms in non-small cell lung cancer. Oncol Lett. 2021;21(5):413.
[14] Zheng H, Zhan Y, Liu S, et al. The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications. J Exp Clin Cancer Res. 2018;37(1):226.
[15] Chi Y, Wang JD, Wang J, et al. Long non-coding RNA in the pathogenesis of cancers. Cells. 2019;8(9):1015.
[16] Deng Q, Fang Q, Xie B, et al. Exosomal long non-coding RNA MSTRG.292666.16 is associated with osimertinib (AZD9291) resistance in non-small cell lung cancer. Aging (Albany NY). 2020;12(9):8001–8015.
[17] Wang L, Ma L, Xu F, et al. Role of long non-coding RNA in drug resistance in non-small cell lung cancer. Thorac Cancer. 2018;9(7):761–768.
[18] Wang X, Qi G, Zhang J, et al. Knockdown of long noncoding RNA small nucleolar RNA host gene 12 inhibits cell growth and induces apoptosis by upregulating miR-138 in nonsmall cell lung cancer. DNA Cell Biol. 2017;36(11):892–900.
[19] Zhou B, Li L, Li Y, et al. Long noncoding RNA SNHG12 mediates doxorubicin resistance of osteosarcoma via miR-320a/MCL1 axis. Biomed Pharmacother. 2018;106:850–857.
[20] Zhang Q, Wei Y, Yan Z, et al. The characteristic landscape of IncRNAs classified by RBP-IncRNA interactions across 10 cancers. Mol Biosyst. 2017;13(6):1142–1151.
[21] Zhang T, Beeharry MK, Wang Z, et al. YY1-modulated long non-coding RNA SNHG12 promotes gastric cancer metastasis by activating the miR-218-5p/YWHAZ axis. Int J Biol Sci. 2021;17(7):1629–1643.
[22] Lei W, Wang ZL, Feng HJ, et al. Long non-coding RNA SNHG12 promotes the proliferation and migration of glioma cells by binding to HuR. Int J Oncol. 2018;53(3):1374–1384.
[23] Tu H, Costa M. XIAP’s profile in human cancer. Biomolecules. 2020;10(11):1493.
[24] Zhao WJ, Deng BY, Wang XM, et al. XIAP associated factor 1 (XAF1) represses expression of X-linked inhibitor of apoptosis protein (XIAP) and regulates invasion, cell cycle, apoptosis, and cisplatin sensitivity of ovarian carcinoma cells. Asian Pac J Cancer Prev. 2015;16(6):2453–2458.
[25] Liu Y, Wu X, Sun Y, et al. Silencing of X-linked inhibitor of apoptosis decreases resistance to cisplatin and paclitaxel but not gemcitabine in non-small cell lung cancer. J Int Med Res. 2011;39(5):1682–1692.
[26] Patil R, Kale AD, Mane DR, et al. Isolation, culture and characterization of primary cell lines of human buccal mucosal fibroblasts: a combination of explant enzymatic technique. J Oral Maxillofac Pathol. 2020;24(1):68–75.
[27] Shan G, Zhou X, Gu J, et al. Downregulated exosomal microRNA-148b-3p in cancer associated fibroblasts enhance chemosensitivity of bladder cancer cells by
downregulating the Wnt/beta-catenin pathway and upregulating PTEN. Cell Oncol. (Dordr). 2021;44(1):45–59.

[28] Liu T, Chen G, Sun D, et al. Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDDC4 in oral squamous cell carcinoma. Acta Biochim Biophys Sin (Shanghai). 2017;49(9):808–816.

[29] Ke SB, Qiu H, Chen JM, et al. ALG3 contributes to the malignancy of non-small cell lung cancer and is negatively regulated by MiR-98-5p. Pathol Res Pract. 2020;216(3):152761.

[30] Lin XM, Li S, Zhou C, et al. Cisplatin induces chemoresistance through the PTGS2-mediated anti-apoptosis in gastric cancer. Int J Biochem Cell Biol. 2019;116:105610.

[31] Liu L, Chai L, Ran J, et al. BAI1 acts as a tumor suppressor in lung cancer A549 cells by inducing metabolic reprogramming via the SCD1/HMGCR module. Carcinogenesis. 2020;41(12):1724–1734.

[32] Fu J, Cai H, Wu Y, et al. Elevation of FGDS5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis. Gene. 2020;755:148866.

[33] Wang J, Yang K, Yuan W, et al. Determination of serum exosomal H19 as a noninvasive biomarker for bladder cancer diagnosis and prognosis. Med Sci Monit. 2018;24:9307–9316.

[34] Qin X, Guo H, Wang X, et al. Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5. Genome Biol. 2019;20(1):12.

[35] Dong Y, Xu T, Zhong S, et al. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p. Life Sci. 2019;239:116984.

[36] Cheng C, Song D, Wu Y, et al. RAC3 promotes proliferation, migration and invasion via PYCR1/JAK/STAT signaling in bladder cancer. Front Mol Biosci. 2020;7(218). DOI:10.3389/fmolb.2020.00218

[37] Lin Y, Liu T, Cui T, et al. RNAInter in 2020: RNA interactome repository with increased coverage and annotation. Nucleic Acids Res. 2020;48(D1):D189–D97.

[38] Yu C, Cheng Z, Cui S, et al. circFOX1M1 promotes proliferation of non-small cell lung carcinoma cells by acting as a ceRNA to upregulate FAM83D. J Exp Clin Cancer Res. 2020;39(1):55.

[39] Deng X, Ruan H, Zhang X, et al. Long noncoding RNA CCAL transferred from fibroblasts by exosomes promotes chemoresistance of colorectal cancer cells. Int J Cancer. 2020;146(6):1700–1716.

[40] Lv Q, Dong F, Zhou Y, et al. RNA-binding protein SORBS2 suppresses clear cell renal carcinoma metastasis by enhancing MTUS1 mRNA stability. Cell Death Dis. 2020;11(12):1056.

[41] Jones-Bolin S. Guidelines for the care and use of laboratory animals in biomedical research. Curr Protoc Pharmacol. 2012;Appendix 4:Appendix 4B.

[42] Li L, Wan K, Xiong L, et al. CircRNA hsa_circ_0087862 acts as an oncogene in non-small cell lung cancer by targeting miR-1253/RAB3D axis. Onco Targets Ther. 2020;13:2873–2886.

[43] Lv X, Lian Y, Liu Z, et al. Exosomal long non-coding RNA LINC00662 promotes non-small cell lung cancer progression by miR-320d/E2F1 axis. Aging (Albany NY). 2021;13(4):6010–6024.

[44] Wang Z, Lin M, He L, et al. Exosomal lncRNA SCRT/miR-665 transferring promotes lung cancer cell metastasis through the inhibition of HEY1. J Oncol. 2021;2021:9813773.

[45] Gao L, Tian Q, Wu T, et al. Reduction of miR-744 delivered by NSCLC cell-derived extracellular vesicles upregulates SUV39H1 to promote NSCLC progression via activation of the Smad9/BMP9 axis. J Transl Med. 2021;19(1):37.

[46] Tao Y, Tang Y, Yang Z, et al. Exploration of serum exosomal LncRNA TBHLA and AGAP2-AS1 as promising biomarkers for diagnosis of non-small cell lung cancer. Int J Biomed Sci. 2020;16(3):471–482.

[47] Zhang Y, Xu H. Serum exosomal miR-378 upregulation is associated with poor prognosis in non-small-cell lung cancer patients. J Clin Lab Anal. 2020;34(6):e23237.

[48] Wang P, Chen D, Ma H, et al. LncRNA SNHG12 contributes to multidrug resistance through activating the MAPK/Slug pathway by sponging miR-181a in non-small cell lung cancer. Oncotarget. 2017;8(48):84086–84101.

[49] Xie FW, Liu JC. LncRNA SNHG12 regulates the miR-101-3p/CUL4B axis to mediate the proliferation, migration and invasion of non-small cell lung cancer. Kaohsiung J Med Sci. 2021;37(8):664–674.

[50] Liu Y, Cheng G, Huang Z, et al. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma. Cell Death Dis. 2020;11(7):515.

[51] Lu C, Wei Y, Wang X, et al. DNA-methylation mediated activating of LncRNA SNHG12 promotes temozolomide resistance in glioblastoma. Mol Cancer. 2020;19(1):28.

[52] Zhu L, Zhang X, Fu X, et al. c-Myc mediated upregulation of long noncoding RNA SNHG12 regulates proliferation and drug sensitivity in natural killer/T-cell lymphoma. J Cell Biochem. 2019;120(8):12628–12637.

[53] Jonas K, Calin GA, Pichler M. RNA-binding proteins as important regulators of long non-coding RNAs in cancer. Int J Mol Sci. 2020;21(8):2969.

[54] Zhang T, Beeharry MK, Zheng Y, et al. Long noncoding RNA SNHG12 promotes gastric cancer proliferation by binding to HuR and stabilizing YWHAZ
expression through the AKT/GSK-3beta pathway. Front Oncol. 2021;11:645832.

[55] Zhang X, Lian T, Fan W, et al. Long-Noncoding RNA CASC9 promotes progression of non-small cell lung cancer by promoting the expression of CDC6 through binding to HuR. Cancer Manag Res. 2020;12:9033–9043.

[56] Qin H, Ni H, Liu Y, et al. RNA-binding proteins in tumor progression. J Hematol Oncol. 2020;13(1):90.

[57] Chen Z, Fillmore CM, Hamerman PS, et al. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535–546.

[58] Wang N, Song L, Xu Y, et al. Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling. EBioMedicine. 2019;47:65–77.

[59] Hu Z, Cai M, Zhang Y, et al. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway. Cell Cycle. 2020;19(2):193–206.

[60] Wu H, Mu X, Liu L, et al. Bone marrow mesenchymal stem cells-derived exosomal microRNA-193a reduces cisplatin resistance of non-small cell lung cancer cells via targeting LRRC1. Cell Death Dis. 2020;11(9):801.

[61] Dittmer A, Dittmer J. Carcinoma-associated fibroblasts promote growth of Sox2-expressing breast cancer cells. Cancers (Basel). 2020;12(11):3435.

[62] Meng Q, Luo X, Chen J, et al. Unmasking carcinoma-associated fibroblasts: key transformation player within the tumor microenvironment. Biochim Biophys Acta Rev Cancer. 2020;1874(2):188443.

[63] Su S, Chen J, Yao H, et al. CD10(+)GPR77(+) cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness. Cell. 2018;172(4):841–56 e16.

[64] Wei LY, Lee JJ, Yeh CY, et al. Reciprocal activation of cancer-associated fibroblasts and oral squamous carcinoma cells through CXCL1. Oral Oncol. 2019;88:115–123.

[65] Wang D, Zhao C, Xu F, et al. Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2. Theranostics. 2021;11(6):2860–2875.

[66] Khoo XH, Paterson IC, Goh BH, et al. Cisplatin-resistance in oral squamous cell carcinoma: regulation by tumor cell-derived extracellular vesicles. Cancers (Basel). 2019;11(8):1166.

[67] Tong Y, Yang L, Yu C, et al. Tumor-secreted exosomal lncRNA POU3F3 promotes cisplatin resistance in ESCC by inducing fibroblast differentiation into CAFs. Mol Ther Oncolytics. 2020;18:1–13.

[68] Han M, Qian X, Cao H, et al. lncRNA ZNF649-AS1 induces trastuzumab resistance by promoting ATG5 expression and autophagy. Mol Ther. 2020;28 (11):2488–2502.

[69] Lei Y, Guo W, Chen B, et al. Tumorreleased lncRNA H19 promotes gefitinib resistance via packaging into exosomes in nonsmall cell lung cancer. Oncol Rep. 2018;40 (6):3438–3446.

[70] Ren J, Ding L, Zhang D, et al. Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. Theranostics. 2018;8 (14):3932–3948.

[71] Shen JG, Xu SN, Yin LG. LncRNA NORAD/miR-202-5p regulates the drug resistance of A549/DDP to cisplatin by targeting P-gp. Gen Physiol Biophys. 2020;39 (5):481–489.

[72] Pereira B, Billaud M, Almeida R. RNA-binding proteins in cancer: old players and new actors. Trends Cancer. 2017;3(7):506–528.

[73] Grammatikakis I, Abdelmohsen K, Gorospe M. Posttranslational control of HuR function. Wiley Interdiscip Rev RNA. 2017;8(1). DOI:10.1002/ wrna.1372

[74] Li T, Mo X, Fu L, et al. Molecular mechanisms of long noncoding RNAs on gastric cancer. Oncotarget. 2016;7 (8):8601–8612.

[75] Kang D, Lee Y, Lee JS. RNA-binding proteins in cancer: functional and therapeutic perspectives. Cancers (Basel). 2020;12(9):2699.

[76] Nyati KK, Zaman MM, Sharma P, et al. Arid5a, an RNA-binding protein in immune regulation: RNA stability, inflammation, and autoimmunity. Trends Immunol. 2020;41(3):255–268.

[77] Lucchesi C, Sheikh MS, Huang Y. Negative regulation of RNA-binding protein HuR by tumor-suppressor ECRG2. Oncogene. 2016;35(20):2565–2573.

[78] Zhang X, Zou T, Rao JN, et al. Stabilization of XIAP mRNA through the RNA binding protein HuR regulated by cellular polyamines. Nucleic Acids Res. 2009;37(22):7623–7637.

[79] Shang MJ, Hong DF, Hu ZM, et al. Cisplatin induces apoptosis of hepatocellular carcinoma LM3 cells via down-regulation of XIAP. Eur Rev Med Pharmacol Sci. 2018;22(2):382–387.

[80] Chen Z, Qi T, Qin XP, et al. Long noncoding RNA SNHG12 promotes prostate tumor occurrence and progression via AKT regulation. Biomed Res Int. 2020;2020:8812923.

[81] Chen Q, Zhou W, Du SQ, et al. Overexpression of SNHG12 regulates the viability and invasion of renal cell carcinoma cells through modulation of HIF1alpha. Cancer Cell Int. 2019;19:128.

[82] Tamang S, Acharya V, Roy D, et al. SNHG12: an LncRNA as a potential therapeutic target and biomarker for human cancer. Front Oncol. 2019;9:901.